CN1736381B - 吗啉甲基萘满酮用于制备平滑肌解痉剂的用途 - Google Patents
吗啉甲基萘满酮用于制备平滑肌解痉剂的用途 Download PDFInfo
- Publication number
- CN1736381B CN1736381B CN 200510047044 CN200510047044A CN1736381B CN 1736381 B CN1736381 B CN 1736381B CN 200510047044 CN200510047044 CN 200510047044 CN 200510047044 A CN200510047044 A CN 200510047044A CN 1736381 B CN1736381 B CN 1736381B
- Authority
- CN
- China
- Prior art keywords
- smooth muscle
- spasm
- rabbits
- drugs
- morpholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000002460 smooth muscle Anatomy 0.000 title claims abstract description 24
- MWBBZYFTJCLASU-UHFFFAOYSA-N CC1C(C2=CC=CC=C2CC1)=O.N1CCOCC1 Chemical compound CC1C(C2=CC=CC=C2CC1)=O.N1CCOCC1 MWBBZYFTJCLASU-UHFFFAOYSA-N 0.000 title claims description 11
- 239000000812 cholinergic antagonist Substances 0.000 title abstract description 5
- 229940124575 antispasmodic agent Drugs 0.000 title abstract 3
- 208000005392 Spasm Diseases 0.000 claims abstract description 20
- 208000007101 Muscle Cramp Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 210000000232 gallbladder Anatomy 0.000 claims abstract description 10
- 230000002496 gastric effect Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 206010048994 Bladder spasm Diseases 0.000 claims description 2
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 2
- 208000014181 Bronchial disease Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- 201000009361 ascariasis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 210000000013 bile duct Anatomy 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 22
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract description 21
- 210000000813 small intestine Anatomy 0.000 abstract description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract description 16
- 206010012735 Diarrhoea Diseases 0.000 abstract description 15
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 10
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 10
- 229960004373 acetylcholine Drugs 0.000 abstract description 10
- 239000001103 potassium chloride Substances 0.000 abstract description 10
- 235000011164 potassium chloride Nutrition 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 9
- 229940057995 liquid paraffin Drugs 0.000 abstract description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract description 8
- 235000019341 magnesium sulphate Nutrition 0.000 abstract description 8
- 230000008925 spontaneous activity Effects 0.000 abstract description 8
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 abstract description 6
- 229910001626 barium chloride Inorganic materials 0.000 abstract description 6
- 210000001072 colon Anatomy 0.000 abstract description 6
- 210000002429 large intestine Anatomy 0.000 abstract description 6
- 210000003437 trachea Anatomy 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 abstract description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract description 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 208000002881 Colic Diseases 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 16
- 206010010904 Convulsion Diseases 0.000 description 15
- 230000036461 convulsion Effects 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001141 propulsive effect Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100288498 Mus musculus Large1 gene Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- ZSTAKEHYXGXVEV-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC2=CC=CC=C2C(=O)C1CN1CCOCC1 ZSTAKEHYXGXVEV-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 201000000117 functional diarrhea Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 206010051250 ureteritis Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及医药技术领域,是CY用于制备平滑肌解痉剂的用途。在动物离体实验中,CY能够降低家兔离体小肠自发活动的张力和振幅,舒张乙酰胆碱、氯化钡、氯化钾收缩的家兔离体小肠、结肠、胆囊;舒张乙酰胆碱、氯化钾收缩的家兔离体膀胱、气管。在整体实验中,CY灌胃给药可明显抑制蓖麻油、硫酸镁、液体石蜡所致的小鼠腹泻,还可明显抑制正常小鼠的小肠推进和大肠推进。因此,可以用于制备治疗平滑肌痉挛的解痉剂。如在制备治疗对各种原因引起的胃肠痉挛性绞痛药物、肠易激综合症药物、溃疡性结肠炎引起的胃肠功能紊乱疾病药物中的应用;在制备治疗各种原因导致的功能性腹泻等药物中的应用。
Description
技术领域:
本发明涉及医药技术领域,确切地说是吗啉甲基萘满酮(CY)用于制备平滑肌解痉剂的用途。
背景技术
CY的化学名称是吗啉甲基萘满酮
(3,4-dihydro-2-(4-morpholinylmethyl)-1(2H)-naphthalenone),该化合物于1977年由Welch,Willard M.;Harbert,Charles A.;Sarges,Reinhard;Stratten,Wilford P.;Weissman,等人成功进行合成,并对其镇痛活性进行了考察。结果表明,该化合物有较弱的镇痛活性,但至今未见有关CY舒张平滑肌作用的报道,本发明人经多方面实验筛选,首次发现该化合物具有平滑肌解痉作用。
吗啉甲基萘满酮的化学系统名称是2-(4-吗啉甲基)-1-萘满酮,其合成方法如下
将4.20g(0.028mol)1-萘满酮,2.50g(0.029mol)吗啉与10mL无水甲醇混合,用氯化氢饱和甲醇溶液调节pH=2,再加入2.25g(0.075mol)多聚甲醛,加热回流6h,冷却后析出固体,抽滤,用甲醇洗涤,得白色固体,用无水甲醇重结晶,得到3-(4-吗啉甲基)-1-萘满酮盐酸盐白色固体,产率77.1%.CY易溶于水,不溶于乙醚、乙酸乙酯、环己烷、氯仿,微溶于甲醇、乙醇、丙酮。
发明内容:
本发明对吗啉甲基萘满酮(CY)提供了治疗平滑肌痉挛的用途。
研究表明:平滑肌强烈收缩致痉挛可引起多种疾病,如支气管平滑肌痉挛可致哮喘,胃肠平滑肌痉挛可致腹痛,胆道平滑肌收缩可致胆绞痛,膀胱强烈收缩可致尿频尿急,子宫平滑肌收缩可能致早产,影响胎儿正常发育,所以研究平滑肌解痉药有很大的现实意义,对治疗哮喘、尿频、尿急、缓解各种绞痛等疾病均有指导意义和参考价值。
我们的研究表明:CY能够降低家兔离体小肠自发活动的张力和振幅,舒张乙酰胆碱、氯化钡、氯化钾收缩的家兔离体小肠、结肠、胆囊;舒张乙酰胆碱、氯化钾收缩的家兔离体膀胱、气管。CY灌胃给药可明显抑制蓖麻油、硫酸镁、液体石蜡所致的小鼠腹泻,还可明显抑制正常小鼠的小肠推进和大肠推进。因此,CY可以用于制备治疗平滑肌痉挛的解痉剂。
附图说明:
图1为CY对致痉剂收缩的家兔离体小肠舒张作用的量效曲线,平均值±标准误
图2为CY对致痉剂收缩的家兔离体结肠舒张作用的量效曲线,平均值±标准误
图3为CY对致痉剂收缩的家兔离体胆囊舒张作用的量效曲线,平均值±标准误
图4为CY对致痉剂收缩的家兔离体膀胱舒张作用的量效曲线,平均值±标准误。
图5为CY对致痉剂收缩的家兔离体气管舒张作用的量效曲线,平均值±标准误
具体实施方式:
一、离体实验
1、动物:新西兰兔,雌雄兼用,体重2.0~2.5kg,沈阳药科大学实验动物中心提供,合格证号:SCXK(辽)2003-008
1、仪器:
(1)HSS-1(B)型恒温浴槽:成都仪器厂
(2)RM6240B型多道生理信号采集处理系统:成都仪器厂
(3)JZJ01型肌肉张力换能器:成都仪器厂
(4)TG-328A电光分析天平:上海天平仪器厂
(5)T-500型电子天平:常熟双杰测试仪器厂
(6)医用供氧器:河北省冀州市福利医疗器械厂
(7)微量移液器:上海荣泰生化工程有限公司
2、试剂
(1)氯化钠(NaCl):天津市大茂化学试剂厂产品,批号:20041121
(2)氯化钾(KCl):沈阳化学试剂厂产品,批号:9908011
(3)硫酸镁(MgSO4·7H2O):开原化学试剂厂产品,批号:990201
(4)磷酸二氢钠(NaH2PO4):沈阳化学试剂厂产品,批号:9804012
(5)无水氯化钙(CaCl2):天津市博迪化工有限公司产品,批号:20020910
(6)碳酸氢钠(NaHCO3):天津市博迪化工有限公司产品,批号:20040406
(7)葡萄糖(Glucose):沈阳化学试剂厂产品,批号:2001030811
(8)氯化钡(BaCl2):沈阳市兴东试剂厂产品,批号:2000928
(9)磷酸氢二钾(KH2PO4):天津市博迪化工有限公司产品,批号:20021231
(10)乙酰胆碱(ACh):北京市东环联合化工厂产品,批号:20041125
4、实验方法
4.1对家兔离体小肠自发活动的作用:待标本张力稳定后,向浴管中分别加入不同浓度的CY(10-4mol/L、0.3×10-4mol/L、10-3mol/L)0.1ml和溶剂水,观察并记录每种浓度下小肠收缩曲线的变化,记录给药前、给药后0、5、10、15、20分钟时的张力、振幅和频率的变化。实验数据以均值±标准差表示,并作配对t检验,判定差异的显著性。
4.2对致痉剂引起的家兔离体小肠、结肠、胆囊、膀胱、气管收缩的作用:待标本张力稳定后,向浴管中加入致痉剂(氯化乙酰胆碱1mg/ml,氯化钡10%,氯化钾60mmol/L),获得最大收缩后,充分冲洗组织,加入同浓度的致痉剂再次诱导对照收缩,当与前一次收缩基本一致后,分别累计加入CY(10-5mol/L~10-3mol/L),记录量效曲线。以致痉剂的最大收缩幅度为100%,绘制量效曲线,数据以平均值±标准误表示,并求出EC50。
5、实验结果:(表1~表8,图1~图5),由表和图可知CY能够降低家兔离体小肠自发活动的张力和振幅,舒张乙酰胆碱、氯化钡、氯化钾收缩的家兔离体小肠、结肠、胆囊;舒张乙酰胆碱、氯化钾收缩的家兔离体膀胱、气管。
6、
*p<0.05**p<0.01同给药前相比,Student’s t-test
*p<0.05**p<0.01同给药前相比,Student’s t-test
*p<0.05同给药前相比,Student’s t-test
二、整体实验
1、动物:昆明种小鼠,雄性,体重18~22g,沈阳药科大学实验动物中心提供,合格证号:SCXK(辽)2003-008
2、仪器:TG328A分析天平(上海天平仪器厂);T-500型电子天平(常熟双杰测试仪器厂)
3、试剂
(1)盐酸吗啡注射液:每支规格10mg/ml,沈阳第一制药厂,批号:002747
(2)蓖麻油:沈阳市虎石台化学试剂厂,批号:940805
(3)硫酸镁:开原化学试剂厂,批号:890201
(4)液体石蜡:沈阳市和平化工厂,批号:911109
(5)活性炭粉:天津市大茂化学试剂厂,批号:20040305
(6)氯化钠注射液:沈阳志鹰制药厂,批号:04090702
4、实验方法
4.1对蓖麻油、硫酸镁、液体石蜡所致腹泻的作用:取体重18~22g健康雄性小鼠50只,随机分为5组,每组10只,标记后称重,各组分别灌胃蓖麻油(硫酸钠、液体石蜡)0.2ml/10g,30min后,第一组生理盐水0.2ml/10g灌胃作为阴性对照;第二组吗啡0.2ml/10g灌胃作为阳性对照;第三、四、五组分别灌胃给予CY 27.72mg/kg、13.86mg/kg、6.93mg/kg,给药容量均为0.2ml/10g。给药后将小鼠分别单个置于铺有12.5×23.0cm的白色滤纸的塑料鼠笼内,每隔1h换一次垫纸,以正常鼠便为0分,软便为0.5分,稀便或水样便为1.0分,计算小鼠腹泻次数,连续观察4~5h,统计数据。
4.2对正常小鼠小肠推进的影响:取体重18~22g健康雄性小鼠50只,随机分为5组,每组10只,实验前禁食不禁水20-24h,标记后称重,第一组生理盐水0.2ml/10g灌胃作为阴性对照;第二组吗啡0.2ml/10g灌胃作为阳性对照;第三、四、五组分别灌胃给予CY 27.72mg/kg、13.86mg/kg、6.93mg/kg,给药容量均为0.2ml/10g,15min后,各组分别灌胃10%活性炭的混悬液0.2ml/10g,再过30min后,小鼠脱臼处死,打开腹腔,分离肠系膜,剪取幽门至回盲部肠管,将小肠平铺于玻璃板上,测量肠管长度为小肠总长度,从幽门至炭粉前沿的长度为炭粉峰的移动距离,按照下式计算炭粉推进百分率,统计数据。炭粉移动百分率=(炭粉移动距离/小肠总长度)×100%。
4.3对正常小鼠大肠推进的影响:取体重18~22g健康雄性小鼠50只,随机分为5组,每组10只,实验前禁食不禁水20-24h,标记后称重,第一组生理盐水0.2ml/10g灌胃作为阴性对照;第二组吗啡0.2ml/10g灌胃作为阳性对照;第三、四、五组分别灌胃给予CY 27.72mg/kg、13.86mg/kg、6.93mg/kg,给药容量均为0.2ml/10g,15min后,各组分别灌胃10%活性炭的混悬液0.2ml/10g,并将小鼠分别单个置于铺有12.5×23.0cm的白色滤纸的塑料鼠笼内,观察并记录小鼠第一次排出黑便的时间,统计数据。
5、实验结果:(表1~表5),由表1~表5可知,CY灌胃给药可明显抑制蓖麻油、硫酸镁、液体石蜡所致的小鼠腹泻,还可明显抑制正常小鼠的小肠推进和大肠推进。
***P<0.001,**P<0.01,*P<0.05与NS组比较
表2.CY对硫酸镁致腹泻小鼠腹泻指数的影响
***P<0.001,**P<0.01,*P<0.05与NS组比较
***P<0.001,**P<0.01,*P<0.05与NS组比较
***P<0.001,**P<0.01,*P<0.05与NS组比较
***P<0.001,**P<0.01,*P<0.05与NS组比较
以上实验结果说明CY能够降低家兔离体小肠自发活动的张力和振幅,舒张乙酰胆碱、氯化钡、氯化钾收缩的家兔离体小肠、结肠、胆囊;舒张乙酰胆碱、氯化钾收缩的家兔离体膀胱、气管。CY灌胃给药可明显抑制蓖麻油、硫酸镁、液体石蜡所致的小鼠腹泻,还可明显抑制正常小鼠的小肠推进和大肠推进。因此,CY可以用于制备治疗平滑肌痉挛的解痉剂。CY可以用于制备治疗对各种原因引起的胃肠痉挛性绞痛药物、肠易激综合症药物、溃疡性结肠炎引起的胃肠功能紊乱疾病药物中的应用;用于制备治疗各种原因导致的功能性腹泻药物中的应用;在制备治疗胆囊炎、胆结石、胆囊蛔虫症引起的胆囊胆道的痉挛性疼痛药物中的应用;也可在在制备治疗膀胱炎、膀胱结石、前列腺炎引起的尿频尿急等膀胱刺激症状及小儿遗尿症药物中的应用;在制备治疗输尿管炎、尿路结石、肾结石引起的肾绞痛药物中应用;在制备治疗各种原因导致的支气管痉挛引起的哮喘疾病药物中的应用。
Claims (3)
1.吗啉甲基萘满酮在制备治疗平滑肌痉挛药物中的应用。
2.根据权利要求1所述的应用,其特征在于:所述的平滑肌痉挛选自支气管平滑肌痉挛、胃肠平滑肌痉挛、胆道平滑肌痉挛和膀胱平滑肌痉挛。
3.根据权利要求1所述的应用,其特征在于:所述的平滑肌痉挛选自各种原因引起的胃肠痉挛;胆囊炎、胆结石、胆囊蛔虫症引起的胆囊胆道的痉挛;膀胱痉挛;各种原因导致的支气管痉挛。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510047044 CN1736381B (zh) | 2005-08-11 | 2005-08-11 | 吗啉甲基萘满酮用于制备平滑肌解痉剂的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510047044 CN1736381B (zh) | 2005-08-11 | 2005-08-11 | 吗啉甲基萘满酮用于制备平滑肌解痉剂的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1736381A CN1736381A (zh) | 2006-02-22 |
| CN1736381B true CN1736381B (zh) | 2010-09-08 |
Family
ID=36079454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510047044 Expired - Fee Related CN1736381B (zh) | 2005-08-11 | 2005-08-11 | 吗啉甲基萘满酮用于制备平滑肌解痉剂的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1736381B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88100346A (zh) * | 1987-01-27 | 1988-11-02 | 默里尔多药物公司 | 3-芳基-5-烷硫基-4h-1,2,4,-三唑 |
| WO1996000725A1 (en) * | 1994-06-28 | 1996-01-11 | American Home Products Corporation | (3,4-dioxocyclobuten-1-yl)chromene, indene, and dihydronaphthalenone derivatives as smooth muscle relaxants |
| CN1150425A (zh) * | 1994-06-10 | 1997-05-21 | 美国家用产品公司 | 用作平滑肌松驰药的环丁-3-烯-1,2-二酮衍生物 |
-
2005
- 2005-08-11 CN CN 200510047044 patent/CN1736381B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88100346A (zh) * | 1987-01-27 | 1988-11-02 | 默里尔多药物公司 | 3-芳基-5-烷硫基-4h-1,2,4,-三唑 |
| CN1150425A (zh) * | 1994-06-10 | 1997-05-21 | 美国家用产品公司 | 用作平滑肌松驰药的环丁-3-烯-1,2-二酮衍生物 |
| WO1996000725A1 (en) * | 1994-06-28 | 1996-01-11 | American Home Products Corporation | (3,4-dioxocyclobuten-1-yl)chromene, indene, and dihydronaphthalenone derivatives as smooth muscle relaxants |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1736381A (zh) | 2006-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith | On the interruption of pregnancy in the rat by the injection of ovarian follicular extract | |
| EP3509638A1 (en) | Cannabidiolic acid esters compositions and uses thereof | |
| CN101775058A (zh) | 一种从乳香中提取的11-羰基-β-乙酰乳香酸及其衍生物的药物制剂的制备和应用 | |
| CN102188438A (zh) | 乙酰天麻素在制备防治血管性痴呆和阿尔茨海默症药物中的应用 | |
| CN1736381B (zh) | 吗啉甲基萘满酮用于制备平滑肌解痉剂的用途 | |
| CN101732440B (zh) | 覆盆子提取物和从中分离得到的覆盆子素及其用途 | |
| CN101856438B (zh) | 一种治疗婴幼儿哮喘的药物组合物及其制备方法和用途 | |
| CN102525909B (zh) | 盐酸戊乙奎醚注射液的制备方法 | |
| CN105919991B (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
| CN100358899C (zh) | 一类抗血小板活化因子化合物 | |
| CN104224863A (zh) | 金钱草总黄酮在制备降低高尿酸血症药物中的应用 | |
| CN102784157B (zh) | 纤细薯蓣皂苷的用途以及含有纤细薯蓣皂苷的药物组合物 | |
| CN102274268A (zh) | 一种具有戒酒作用的中药活性提取物、其制备方法和应用 | |
| JP5364532B2 (ja) | ポリエチレングリコールの誘導体およびそれを有効成分として含む抗腫瘍剤 | |
| CN103705773A (zh) | 一种抗菌消炎中药组合物及其制备方法 | |
| Peacock | On the Prognosis in Cases of Valvular Disease of the Heart | |
| CN101167816B (zh) | 毛茛总苷的制备方法和应用 | |
| CN113694055A (zh) | 沉香四醇在制备治疗血管性痴呆疾病的药物中的应用 | |
| CN101548968B (zh) | 色满类化合物hef-19用于制备肠管平滑肌解痉剂及止泻剂的用途 | |
| US20190000908A1 (en) | Compositions and methods for treating and/or preventing a urinary tract infection | |
| CN103893227B (zh) | 山木瓜枝提取物及其应用 | |
| CN101612160B (zh) | 化合物20(S)-人参皂苷Rh2在制备抗抑郁症药物中的应用 | |
| CN102488675B (zh) | 一种黄酮化合物预防或治疗炎症性疾病的用途 | |
| CN112168831B (zh) | 一个雷公藤内酯醇衍生物在防治炎症性肠病中的用途 | |
| TW534813B (en) | Treating agent for diseases due to infection with helicobacter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100908 Termination date: 20150811 |
|
| EXPY | Termination of patent right or utility model |